



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

THOMSON MEDICAL GROUP LIMITED SECURES S\$225,000,000 ISLAMIC REVOLVING CREDIT FACILITY (RCF-i) WITH OPTION TO CONVERT INTO A SUSTAINABILITY-LINKED RCF-i

The Board of Directors of Thomson Medical Group Limited (the “Company” or “TMG”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has secured a S\$225,000,000 Islamic-linked loan facility (“RCF-i”) with potential conversion to a sustainability-linked facility. The murabahah agreement dated 21 August 2025 (the “Murabahah Agreement”) is entered into by (i) the Company and Thomson Medical Pte. Ltd. (“TMPL”), a wholly owned subsidiary of the Company, as customers (ii) Malayan Banking Berhad, Singapore Branch (“Maybank”), as original financier (in such capacity, the “Financier”), mandated lead arranger, agent and security agent, and (iii) Maybank Investment Bank Berhad, as sustainability structuring adviser (the “Sustainability Structuring Adviser”). This marks the first Islamic-linked loan facility secured by the Group.

Under the terms of the Murabahah Agreement, TMG may, within 12 months, request that the facility be classified as a sustainability-linked facility (“SLF”), subject to meeting certain agreed conditions including, amongst others, agreement between TMG and Maybank on certain Sustainability Performance Targets (“SPTs”) that will underpin the facility’s margin adjustment mechanism.

Other salient provisions of the Murabahah Agreement include an undertaking by TMG to ensure that it remains, at all times, listed on the official list of the Singapore Exchange Securities Trading Limited; and a mandatory early settlement event, if (i) TMG ceases to have direct control over Sasteria Pte. Ltd. or (ii) TMG ceases to have indirect control over TMPL, Sasteria (M) Pte. Ltd., TMC Life Sciences Berhad, FVH Singapore Pte. Ltd. or Far East Medical Vietnam Limited.

TMG will use the proceeds from the facility to fully repay the principal, interest and other amounts owing (including outstanding loan amounts) under its existing revolving credit facility and related costs due in October 2025 and towards funding the Group’s working capital requirements, capital expenditure, business acquisition, other investments and/or for general corporate purposes.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group Chief Executive Officer
21 August 2025